Macrolide Antibiotics Market Expected to Reach $7.0 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Macrolide Antibiotics Market," The macrolide antibiotics market size was valued at $5.6 billion in 2022, and is estimated to reach $7.0 billion by 2032, growing at a CAGR of 2.3% from 2023 to 2032. Macrolides antibiotics are a class of anti-infective drugs used to treat bacterial infections that typically affect lungs, skin, or soft tissues. They are also used for the treatment of sexually transmitted diseases and other infections caused due to bacterial strains, including Borrelia burgdorferi, Campylobacter species, Chlamydia trachomatis, Chlamydophila pneumoniae, Corynebacterium diphtheriae, Legionella species, and others.  This propels the macrolide antibiotics market share. 

In addition, the macrolide antibiotics market trends includes the rise in population and rise in healthcare costs. The prevalence of bacterial infections rises with increases in population, thus increasing the need for medicines such as macrolides. The improvement in accessibility to healthcare services and prescriptions is greatly supported by a rise in healthcare spending, especially in developing nations. More people are able to access proper medical care as healthcare infrastructure and resources advance, increasing the demand for effective antibiotics. The market expands as a result of the population growth and rise in healthcare costs, which expands the patient base in need of macrolide medications to treat bacterial infections. 

On the basis of drug type, the macrolide antibiotics market is segmented into azithromycin, erythromycin, and others. The azithromycin segment dominated the market in terms of revenue in 2022, owing to the high prescription rate of azithromycin by healthcare professionals around the globe. In addition, azithromycin is used on a large scale for the treatment of infections such as bronchitis, pneumonia, sexually transmitted diseases (STD), and infections of the ears, lungs, skin, and throat, which increases its demand in the market.  

On the other hand, the others segment is anticipated to grow at the fastest rate during the forecast period, owing to recent research and development related to products in this segment. This is further anticipated to increase the product approvals and launches in the market thereby fostering macrolide antibiotics market share. 

By route of administration, the market is bifurcated into oral, parenteral, and others. The oral segment dominated the market in terms of revenue in 2022 and is anticipated to be the fastest growing segment during the forecast period. The growth of the oral segment is mainly attributed to factors such as patient preference, improved formulations, ease of administration, and cost effectiveness.  

By indication, the respiratory tract infections segment dominated the market in terms of revenue in 2022, owing to surge in incidences of bacterial infections such as common cold, influenza, bronchitis, and pneumonia around the globe and significant adoption of macrolide antibiotics for the treatment of these infections.  

By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores and retail pharmacies segment dominated the market in terms of revenue in 2022, owing to the accessibility of a broad range of macrolide medications at retail pharmacies to fulfill consumer needs. In addition, pharmacists are essential in assessing prescriptions, assuring adequate dosages, and educating patients on how to use medications and any possible adverse effects, all of which contribute to the segment growth. 

However, the online providers segment is anticipated to grow at a fastest rate during the macrolide antibiotics market forecast period. Online providers enable the customers to choose from a variety of brands, formulations, and dosages, ensuring that they find the specific medication that meets the specific needs. 

Region-wise, macrolide antibiotics market analysis is done accross, North America, Europe, Asia-Pacific and LAMEA. The Asia-Pacific held the largest market share in 2022 and is projected to exhibit the highest CAGR in the market during the forecast period. This growth can be attributed to several factors, including an increase in healthcare expenditure and the implementation of governmental initiatives aimed at modernizing healthcare infrastructure. Moreover, the high prevalence of infectious diseases and high rate of antibiotic prescription in this region also contributes to the macrolide antibiotics market size. 

However, overuse and misuse of available antibiotics has led to the rise in burden of antimicrobial resistance. This results in reduced treatment efficiency and higher cost of treatment of infections, which may hamper the market growth to some extent. However, rise in R&D activities to overcome the antimicrobial resistance and launch of novel macrolide antibiotics are expected to offer lucrative opportunities for the growth of the market in this region during the macrolide antibiotics market forecast period. 

Key Findings of the Study  

• By drug type, the azithromycin segment was highest contributor to the macrolide antibiotics industry in 2022 and the others segment is anticipated to grow at a fastest rate during the forecast period.  

• By route of administration, the oral segment was the highest contributor to the market in 2022 in terms of revenue and is anticipated to grow at a fastest rate during the forecast period.  

• By indication, the respiratory tract infections segment dominated the market in terms of revenue in 2022 and is anticipated to be the fastest growing segment during the forecast period.  

• By distribution, the drug store & retail pharmacies segment dominated the market in 2022. However, the online providers segment is anticipated to grow at the highest CAGR during the forecast period.  

• Region-wise, Asia-Pacific generated the largest revenue in 2022 in macrolide antibiotics industry and is anticipated to grow at the highest CAGR during the forecast period.